Learn more about me:
Recent Posts
Appointment Information
La Crosse, WI
Hospital
700 West Ave. S., La Crosse, WI 54601Provider's Bio
I try to connect with my patients as individuals and use this understanding to move forward in shared decision-making about medical care. I am honored to be part of the team serving my patients.
In my free time, I enjoy traveling, cooking and staying active outside.
Training & Credentials
Education
- Medical College of Wisconsin
Internship/Residency
- Internal Medicine, Washington University School of Medicine
Fellowship
- Chief Resident, Washington University School of Medicine
Certification
- Internal Medicine, American Board of Internal Medicine
Membership
- Society of Hospital Medicine
Academic Appointment
- Assistant Professor of Medicine, Mayo Clinic College of Medicine and Science
Special Interests
- Benign breast disease
- Breast cancer survivorship and surveillance
- Breast lump
- Breast pain
- Contraception
- Dense breast tissue and supplemental screening
- Evaluation, counseling and management of patients with breast cancer-related genetic mutations and family history of breast cancer
- High-risk breast lesions, including atypical hyperplasia and lobular carcinoma in situ
- Irritable bowel
- Menopause
- Mental health
- Migraines
- Preventive medications to decrease risk of breast cancer
- Sexual health
- STI screening
- Video visits or telehealth
- Wellness and exercise
- Women's health
Research & Publications
- Prevalence, impact, and diagnostic challenges of benign breast disease: A narrative review, May 2023.
- Clinical implications and utility of polygenic risk scores in women at elevated risk for breast cancer, September 2022.
- Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19, December 2021.
- Computer-based patient bias and misconduct training impact on reports to incident learning system, November 2021.
- Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019, October 2021.